A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

This study is testing an experimental drug called CLN-978 — given as an injection under the skin — in people with Sjögren's disease (an autoimmune condition that causes dry eyes, dry mouth, and fatigue). CLN-978 is designed to target and reduce certain immune cells (B cells) that drive the disease. This is a first study in humans for this type of treatment approach. **You may be eligible if...** - You have been diagnosed with Sjögren's disease for at least 24 weeks - Your disease is moderately to severely active based on standard assessments - Your blood counts (white cells, B cells, platelets, hemoglobin) meet the required levels - Standard disease-modifying treatments have not worked well enough **You may NOT be eligible if...** - You have another serious autoimmune condition requiring active treatment - You have had certain infections (such as active tuberculosis or hepatitis B or C) - You have had a significant cancer diagnosis in recent years - You have severely abnormal liver or kidney function - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.